

# Summary Report of Consolidated Financial Results

For the Nine Months Period ended December 31, 2012



February 12, 2013  
TSE/OSE-1<sup>st</sup> section

Company name: NIPRO CORPORATION

Code No.8086 URL: <http://www.nipro.co.jp/>

Representative: Yoshihiko Sano, President and Representative Director

Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division TEL: (06)6372-2331

Filing date of quarterly reporting: February 14, 2013

Payment date of cash dividends: -

Supplemental material on quarterly reporting: No

Presentation on quarterly results: No

(Note: Amounts are truncated to one million yen)

## 1. Consolidated Results for the Nine Months ended December 31, 2012 (From April 1, 2012 to December 31, 2012)

### (1) Consolidated Results of Operations

(Note: % of change from the same period a year ago)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
9 months ended December 31, 2012	181,125	13.5	9,796	(27.5)	11,457	18.4	10,388	345.5
9 months ended December 31, 2011	159,644	9.9	13,509	(5.4)	9,680	(2.8)	2,331	(41.7)

Note: Comprehensive income 9 months ended December 31, 2012: 739 million yen (-%) 9 months ended December 31, 2011: (20,577) million yen (-%)

	Earnings per share	Diluted Earnings per share
	Yen	Yen
9 months ended December 31, 2012	60.91	54.95
9 months ended December 31, 2011	18.38	16.09

### (2) Consolidated Financial Position

	Total Assets	Net Assets	Equity Ratio
	Millions of yen	Millions of yen	%
9 months ended December 31, 2012	518,198	114,676	20.6
Year ended March 31, 2012	499,686	113,950	22.0

Note: Equity 9 months ended December 31, 2012: 106,655 million yen Year ended March 31, 2012: 109,820 million yen

## 2. Dividends

	Annual Dividends per Year				
	First-quarter	Second-quarter	Third-quarter	Year-end Dividends	Annual Dividends
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2012	-	12.00	-	11.50	23.50
Year ending March 31, 2013	-	12.00	-		
Year ending March 31, 2013 (Forecast)				8.50	20.50

Note: Revisions to the forecast of cash dividends in the current quarter: No

## 3. Forecast of Consolidated Financial Results for the Year ending March 31, 2013 (From April 1, 2012 to March 31, 2013)

(Note: The % displays in the line of year ending March 31, 2013 show increase/decrease ratio against the year ended March 31, 2012)

	Net Sales		Operating Income		Ordinary Income		Net Income		Earnings per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Year ending March 31, 2013	241,000	13.7	13,500	(14.7)	11,500	(4.0)	9,750	112.6	57.17

Note: Revisions to the forecast of consolidated financial results in the current quarter: No

\*Notes

(1) Change in Significant Subsidiaries during the Current Period  
(Change in specified subsidiaries caused a change in the scope of consolidation): No  
Additional: 0 Removal: 0

(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No

(3) Change in Accounting Policies and Accounting Estimate and Restatement  
[1] Changes in accounting policies by a newly issued accounting pronouncement : Yes  
[2] Changes other than [1] : No  
[3] Change in accounting estimate : Yes  
[4] Restatement : No

Note: Depreciation method was changed from the first-quarterly result, which is applied to "Changes in accounting policies which are difficult to distinguish from changes in accounting estimates". Detailed information can be found in P.3 "2. Summary Information (3)Change in Accounting Policies and Accounting Estimate and Restatement" in the attachment.

(4) Issued Shares (Common stock)

[1] Number of issued shares at end of the period (including treasury stock)

9 months ended December 31, 2012 : 171,459,479shares

Year ended March 31, 2012 : 171,459,479 shares

[2] Number of treasury stock at end of the period

9 months ended December 31, 2012 : 913,775 shares

Year ended March 31, 2012 : 913,612 shares

[3] Average number of shares during the period

9 months ended December 31, 2012 : 170,545,818 shares

9 months ended December 31, 2011 : 126,843,635 shares

\*Information regarding the quarterly review procedure

This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments and Exchanges Act. It is under the review procedure process at the time of disclosure of this report

\*Disclaimer regarding projection information including appropriate use of forecasted financial result, and other special notes

The projection figures shown above are based on information that was available at the time of preparation and may contain certain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstances and other developments. More information concerning these forecasts can be found in P.3 "1. Qualitative information for the nine months period ended December 31, 2012, (3) Qualitative information concerning forecast of consolidated financial results" in the attachment.

## Table of Contents

1. Qualitative Information for the Nine-Month Period ended December 31, 2011 .....	2
(1) Qualitative Information Concerning Consolidated Financial Results .....	2
(2) Qualitative Information on the Consolidated Financial Position .....	3
(3) Qualitative Information Concerning Forecast of Consolidated Financial Results .....	3
2. Summary (Other) Information .....	3
(1) Changes in Significant Consolidated Subsidiaries .....	3
(2) Accounting Treatments Simplified or Unique for Preparation .....	3
(3) Changes in Accounting Policies and Accounting Estimate and Restatement .....	3
3. Consolidated Financial Statements .....	4
(1) Quarterly Consolidated Balance Sheets .....	4
(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive Income .....	6
Quarterly Consolidated Statements of Income .....	6
Quarterly Consolidated Statements of Comprehensive Income .....	6
(3) Notes Related to Going Concern .....	7
(4) Segment Information .....	7
(5) Notes to Statements of Shareholders' Equity, If Having Significant Variation .....	8
(6) Material Subsequent Event .....	9

## 1. Qualitative Information for the Nine-Month Period ended December 31, 2012

### (1) Qualitative Information Concerning Consolidated Financial Results

In the current quarter period under review (quarter ended December 31, 2012), uncertain outlook for the global economy was getting sever because the recession of American economy was accelerated by the exposure of “fiscal cliff” problem and debt crisis has continued in Europe.

Japanese economy, on the other hand, was slowly recovering with the demand for reconstruction from Great East Japan Earthquake but still under harsh management condition due to protracted deflation and struggling export associated with deceleration of overseas economy.

Under such situation, the Nipro Group continued to work hard for expanding and enforcing our manufacturing and sales bases in order to increase our sales and improve our profit.

As a result, the consolidated sales in the nine-months of fiscal year 2012 increased 13.5% from the same period of the previous year to 181,125 million yen. As for the profit, consolidated operating income decreased 27.5% from the same period of the previous year to 9,796 million yen because of an increase in selling, general and administrative expenses, and consolidated ordinary income increased 18.4% from the same period of the previous year to 11,457 million yen due to a cause of foreign exchange gains and a decrease in non-operating expenses. The consolidated net income increased 345.5% to 10,388 million yen due to a cause of gain on sales of investment securities and a decrease in extraordinary losses.

The overviews of the results by segment in the current period are as follows.

#### [1] Medical-related Business

Looking at the domestic market, business conditions remained extremely severe because the market competition was intensified due to the effect of revision of medical treatment fee and the reduction of official prices for drugs and medical materials. However, each product group recorded good sales as a result of our aggressive sales activities and improvement of sales efficiency aiming to increase our share.

Our medical-equipment-related products such as dialysis system and our dialysis-related products such as HDF filter, blood circuits and dialysis pharmaceuticals showed strong growth. The sales of our testing-related products such as glucose analysis device (POCT) and vacuum blood drawing system, enteral-alimentation-related products and injection-transfusion-related products also steadily increased.

As for the overseas sales, the sales of dialysis-related products such as dialyzer and blood glucose monitoring device showed significant increase as a result of our fine promotion of dialysis-related and diabetes-related products in close relation to medical front.

This November, we acquired Nefro-Ion, S.L., dialysate manufacturer in Spain, for further promotion in European dialysis market with a good selection of dialysis related products. This September, we established new sales base in Pakistan, where the future demand is expected with 180 million populations, to enforce community-based sales activity in Central Asia.

In addition, based on the idea of “local production for local consumption”, we established a new department in order to realize an early development and introduction of desirable products in medical front, and tried to expand our sales meeting customer needs in each country.

On the other hand, India plant has started manufacturing from this November, and plants in Indonesia and Bangladesh also have started their operation from this December. We will continue to work harder for promoting to establish our brand image and reinforce our sales system.

As a result, net sales of this business increased 15.9% from the same period of the previous year to 125,566 million yen.

#### [2] Pharmaceutical-related Business

This business consists of four main divisions: the Generic Drugs Division, providing low cost and high quality medical drugs, the Contracted Manufacturing Division, offering high value-added products to meet customer needs, the Collaborative Promotion Division, handling generic drugs featuring our unique pharmaceutical technique, and Pharmaceutical Division, integrating the development division of suitable container and dosing device for each pharmaceutical.

Sales of generic drugs are expected to grow in line with the market, due in part to a government policy for the dissemination of the market for generic drugs to over 30% by the end of fiscal year 2012. Consequently a number of policies have been implemented to encourage the use of generic products. Major pharmaceutical manufacturers have made a full-scale entry into the Japanese market and foreign generic manufacturers have strengthened their marketing strategies, making the competitive environment surrounding the domestic market more severe.

Under these conditions, we have tried to increase the share of the oral drug through reinforcing our sales promotions to dispensing pharmacies and by the close co-operation with drug wholesalers. In addition, as a result of our detailed information service provided mainly to large hospital, the sales in the current period showed steady increase.

Looking at sales of our contracted manufacturing business, we have worked hard at realizing a variety of detailed services such as contracted development and supporting high value-added initiatives other than OEM manufacturing of other companies' brand. In addition, contracted manufacturing was driven by collaborate manufacturing with generic sales division and new drug development division of domestic and foreign major pharmaceutical manufacturers, and the sales in the current period exceeded those in the same period of the previous year.

As for the pharmaceutical containers, medical-preparation- and administration-related devices, the sales showed good increase with our container and system suitable for each pharmaceuticals such as bags for antimicrobial agent and pre-filled syringes as well as rubber stoppers for pharmaceutical and vaccine use and kit form containers. These systems were provided by both of self- development and joint development with pharmaceutical companies based on our processing techniques for plastics, metal and rubber in order to meet the diverse needs in the medical front.

Furthermore, under the restrictive policy for medical cost, we continue to promote contract manufacturing and development cooperating with domestic and foreign pharmaceutical companies in general life cycle management of pharmaceuticals, which includes the development of combination products, systematization for self-injection and modification of dosage form.

As a result, net sales of this business increased 9.2% from the same period of the previous year to 50,149 million yen.

### [3] Glass-related Business

As for the sales of material glass tube for ampoule and for tube bottles, export sales decreased but total sales increased from the same period of the previous year thanks to the fine sales of material glass tube for tube bottles in Japan even though the sales for ampoule decreased.

On the other hand, the sales of tube bottles remained flat from the same period of the previous year because of the continuous order that we acquired last year. The pharmaceutical glass business in China was affected by the boycott campaign to Japanese products, but the sales increased a little from the same period of the previous year.

The sales of glass for thermos bottles decreased from the same period of the previous year due to the decrease in demand of glass thermos bottles after the Great East Japan Earthquake, and as for glass for lighting purpose, the order of material glass tube for electric lamp and electric lamp production decreased by the boycott campaign of Japanese products in China and the sales decreased from the same period of the previous year.

As a result, net sales of this business increased 0.9% from the same period of the previous year to 5,233 million yen

### [4] Other Business

In the other business, the sales from real estate rental income decreased 12.2% from the same period of the previous year to 176 million yen.

## (2) Qualitative Information on the Consolidated Financial Position

### Analysis Concerning the Conditions of Assets, Liabilities and Net Assets

Total assets increased 18,512 million yen from the end of the previous period to 518,198 million yen. Current assets increased 3,020 million yen mainly due to the increase of 11,692 million yen in notes and accounts receivable-trade, and noncurrent assets increased 15,491 million yen mainly due to the increase of 11,683 million yen in buildings and structures.

Total liabilities increased 17,785 million yen from the end of the previous period to 403,521 million yen. Current liabilities decreased 947 million yen mainly due to the decrease of 10,000 million yen in commercial paper, and noncurrent liabilities increased 18,733 million yen mainly due to the increase of 17,094 million yen in long-term loans payable.

Total net assets increased 726 million yen from the end of the previous period to 114,676 million yen. Shareholders' equity increased 6,557 million yen and accumulated other comprehensive income decreased 9,723 million yen.

## (3) Qualitative Information Concerning Forecast of Consolidated Financial Results

In the world economy in the future, we are still under the unpredictable situation caused by debt crisis in Europe and economic downturn in America. In Japan, economic boost policies conducted by new administration are expected but we still need to pay attention the way to full-scale departure from deflation.

In such situation, we will aim to promote our sales performance with a huge selection and high-value added products.

At this moment, there is no revise to the consolidated financial results for the fiscal year 2012 which was published November 9, 2012.

## 2. Summary (Other) Information

### (1) Changes in Significant Consolidated Subsidiaries

N/A

### (2) Accounting Treatments Simplified or Unique for Preparation

N/A

### (3) Change in Accounting Policies and Accounting Estimate and Restatement

(Changes in accounting policies which are difficult to distinguish from changes in accounting estimates)

Effective from the first quarter of the current fiscal year, the Company and its domestic subsidiaries changes the depreciation method for the relevant tangible assets newly acquired from April 1, 2012 according to the amendment of Corporation Tax Act in Japan.

As a result, consolidated operating income, consolidated ordinary income and consolidated net income increased by 191 million yen for each compared with the previous method.

3. Consolidated Financial Statements

(1) [ Quarterly Consolidated Balance Sheets]

(Amount: million yen)

	As of March 31, 2012	As of December 31, 2012
<b>Assets</b>		
<b>Current Assets</b>		
Cash and deposits	95,737	83,062
Notes and accounts receivable-trade	68,641	80,333
Merchandise and finished goods	48,114	48,658
Work in process	8,753	9,053
Raw materials and supplies	14,736	16,634
Deferred tax assets	4,829	4,315
Other	9,983	11,754
Allowance for doubtful accounts	(360)	(355)
<b>Total current assets</b>	<b>250,435</b>	<b>253,456</b>
<b>Noncurrent assets</b>		
<b>Property, plant and equipment</b>		
Buildings and structures	116,878	131,845
Accumulated depreciation and impairment loss	(63,320)	(66,603)
Buildings and structures, net	53,558	65,241
Machinery, equipment and vehicles	142,067	154,053
Accumulated depreciation and impairment loss	(103,263)	(112,044)
Machinery equipment and vehicles, net	38,804	42,009
Land	20,446	21,662
Lease assets	1,680	2,007
Accumulated depreciation	(735)	(998)
Lease assets, net	944	1,009
Construction in progress	26,957	28,581
Other	28,317	30,338
Accumulated depreciation and impairment loss	(23,350)	(24,522)
Other, net	4,967	5,815
<b>Total property, plant and equipment</b>	<b>145,678</b>	<b>164,320</b>
<b>Intangible assets</b>		
Goodwill	11,894	11,227
Lease assets	305	363
Other	6,950	9,874
<b>Total intangible assets</b>	<b>19,151</b>	<b>21,465</b>
<b>Investments and other assets</b>		
Investment securities	71,829	59,422
Deferred tax assets	6,597	10,913
Other	8,954	11,702
Allowance for doubtful accounts	(2,961)	(3,082)
<b>Total investments and other assets</b>	<b>84,420</b>	<b>78,956</b>
<b>Total noncurrent assets</b>	<b>249,250</b>	<b>264,741</b>
<b>Total assets</b>	<b>499,686</b>	<b>518,198</b>

(Amount: million yen)

	As of March 31, 2012	As of December 31, 2012
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable-trade	37,721	41,370
Short-term loans payable	104,131	109,910
Commercial papers	10,000	—
Current portion of bonds	10,000	10,000
Lease obligations	426	711
Accounts payable-other	6,036	5,780
Accrued directors' bounuses	153	—
Income taxes payable	3,276	1,839
Provision for bounuses	2,308	2,083
Provision for directors' bounuses	43	215
Provision for loss on business liquidation	1,954	1,954
Notes payable-facilities	3,399	3,940
Other	9,636	10,334
Total current liabilities	189,089	188,142
Noncurrent liabilities		
Bonds payable	34,000	34,000
Convertible bond-type bonds with subscription rights to shares	15,000	15,000
Long-term loans payable	140,380	157,474
Lease obligations	914	1,668
Deferred tax liabilities	1,761	2,130
Provision for retirement benefits	1,987	2,475
Provision for directors' retirement benefits	702	723
Provision for loss on litigation	170	218
Other	1,729	1,688
Total noncurrent liabilities	196,645	215,379
Total liabilities	385,735	403,521
<b>Net assets</b>		
Shareholders' equity		
Capital stock	84,397	84,397
Capital surplus	636	636
Retained earnings	48,389	54,946
Treasury stock	(864)	(864)
Total shareholders' equity	132,558	139,115
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(6,528)	(14,504)
Foreign currency translation adjustment	(16,209)	(17,956)
Total accumulated other comprehensive income	(22,737)	(32,460)
Minority interests	4,129	8,021
Total net assets	113,950	114,676
Total liabilities and net assets	499,686	518,198

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]  
 Quarterly Consolidated Statements of Income

(Amount: million yen)

	FY2011 first nine months (From April 1, 2011 to December 31, 2011)	FY2012 first nine months (From April 1, 2012 to December 31, 2012)
Net sales	159,644	181,125
Cost of sales	111,398	131,154
Gross profit	48,246	49,971
Selling, general and administrative expenses	34,736	40,175
Operating income	13,509	9,796
Non-operating income		
Interest income	414	618
Dividends income	942	1,744
Foreign exchange gains	—	1,433
Other	608	683
Total non-operating income	1,966	4,480
Non-operating expenses		
Interest expenses	2,467	2,553
Foreign exchange losses	2,795	—
Equity in losses of affiliates	69	38
Other	463	228
Total non-operating expenses	5,795	2,819
Ordinary income	9,680	11,457
Extraordinary income		
Gain on sales of noncurrent assets	117	35
State subsidy□	89	40
Gain on sales of investment securities	—	4,159
Other	10	91
Total extraordinary income	218	4,326
Extraordinary loss		
Loss on retirement of noncurrent assets	296	152
Impairment loss	470	1
Loss on disaster	1,018	—
Settlement package	—	119
Other	448	183
Total extraordinary losses	2,234	456
Income before income taxes and minority interests	7,664	15,327
Income taxes-current	4,115	4,391
Income taxes-deferred	785	247
Total income taxes	4,901	4,638
Income before minority interests	2,762	10,688
Minority interests in income	430	299
Net income	2,331	10,388

[Quarterly Consolidated Statements of Comprehensive Income]

(Amount: million yen)

	FY2011 first nine months (From April 1, 2011 to December 31, 2011)	FY2012 first nine months (From April 1, 2012 to December 31, 2012)
Income before minority interests	2,762	10,688
Other comprehensive income		
Valuation difference on available-for-sale securities	(16,312)	(7,977)
Foreign currency translation adjustment	(7,027)	(1,971)
Total other comprehensive income	(23,340)	(9,949)
Comprehensive income	(20,577)	739
Comprehensive income attributable to owners of the parent	(20,915)	664
Comprehensive income attributable to minority interests	337	74



(3) Notes Related to Going Concern  
N/A

(4) Segment Information

I FY2011 (From April 1, 2011 to December 31, 2011)

1. Sales and Profit by Reportable Operating Segment

(Millions of yen)

	Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated statement of income (Note.3)
	Medical -related	Pharma- ceutical -related	Glass -related	Total				
Net Sales								
(1)Outside	108,318	45,938	5,187	159,444	200	159,644	-	159,644
(2)Intersegment	970	4,715	351	6,037	33	6,071	(6,071)	-
Total	109,289	50,653	5,538	165,481	234	165,716	(6,071)	159,644
Segment profit	13,072	5,042	399	18,514	168	18,683	(5,173)	13,509

(Notes)

1. "Other" is the business segment which is not included in the segment and consist of real estate income and sales by headquarter.
2. Adjustment for the segment profit of (5,173) million yen includes elimination of inter-segment transaction of 63 million yen and corporate cost of (5,237) million yen. Corporate cost consisted primarily of sales, general and administrative expenses and research and development cost which do not belong to the reporting segment.
3. Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Information on Goodwill by Reportable Operating Segment

N/A

II FY2012 (From April 1, 2012 to December 31, 2012)

1. Sales and Profit by Reportable Operating Segment

(Millions of yen)

	Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated statements of Income (Note.3)
	Medica -related	Pharma- ceutical -related	Glass -related	Total				
Net sales								
(1)Outside	125,566	50,149	5,233	180,949	176	181,125	-	181,125
(2)Intersegment	983	5,208	371	6,562	33	6,596	(6,596)	-
Total	126,549	55,358	5,604	187,512	210	187,722	(6,596)	181,125
Segment profit	11,165	3,511	246	14,923	165	15,088	(5,292)	9,796

(Notes)

1. "Other" is the business segment which is not included in the segment and consist of real estate income and sales by headquarter.
2. Adjustment for the segment profit of (5,292) million yen includes elimination of inter-segment transaction of 278 million yen and corporate cost of (5,571) million yen. Corporate cost consisted primarily of sales, general and administrative expenses and research and development cost which do not belong to the reporting segment.
3. Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Change in Reportable Segment

(1) From this third quarter period ended December 31, 2012, the name of business segment was changed partially and "Materials" is displayed as "Glass-related".

This change is just only for the name, and there is no difference about business segment itself from the same period of the previous year.

(2) The reportable segment of Nipro Glass India Ltd., Nipro Tube Glass Ltd., Nipro Glass Americas Corporation, Nipro Glass France S.A.S. and Nipro Glass Belgium N.V. was changed from glass-related business to medical-related business from the period ended March 31, 2012 as a result of reconsideration from the view point of global business strategy.

In addition, entity conversion was conducted from this third quarter period ended December 31, 2012 in order to enforce pharmaceutical-related business and build a strong cooperative relationship between medical-related, pharmaceutical-related and glass-related business. Following this conversion, some business divisions include in glass-related business were changed to pharmaceutical-related business.

Based on this idea, the segment information of the same period of the previous year was revised.

3. Information about Impairment Loss of Tangible Assets and Goodwill by Reportable Operating Segment

N/A

(5) Notes to Statements of Shareholder's Equity, if having Significant Variation

N/A

## (6) Material Subsequent Event

Nipro Corporation resolved to acquire the shares in Goodman Co., Ltd. (stock code 7535, listed on JASDAQ of the Osaka Stock Exchange, the "Target Company"), through a tender offer (the "Tender Offer"), at the board of directors' meeting of the Company held on January 24, 2013.

### 1. Purpose of Tender Offer

Since Nipro Corporation was founded in 1954, we have been pursuing the technology for providing our creative products to improve the patients' QOL and meet the challenges in medical front under our management philosophy of "business activities for society" and our concept of "technological innovation". Today, our medical devices such as dialyzer are used widely from home to abroad because of our trusted technology and quality. Cardiovascular-related products is now planned to be grown as the third pillar of our medical devices business following dialysis-related products and general disposable products, and we promote our products development aiming for a wide selection and new treatment concept in this field.

On the other hand, the Target Company is the first company to focus on the potential of interventional cardiology (diagnosis and treatment of cardiocirculatory disease) which was introduced in 1970s' as a cutting-edge medical technology. The Target Company has developed and introduced the devices for treatment and diagnosis of this field such as catheter, and developed the first software for cardiac function image analysis in Japan as well. Especially as for the catheter products, the Target Company has promoted development and introduction of their products that meet the particular need of Japan based on their experiences, knowledge and knowhow accumulated through their domestic sales activities to establish their strong brand in Japan.

However, the business situation surrounding us has changed dramatically. As the financial burden of medical insurance is reviewed in association with aging society, the government enforces the policy for lower national cost of medical care such as biennial reduction of reimbursement prices of special medical materials, and manufacturers feel a need for making their business more efficient. Moreover, due to rapid upgrading and improvement of medical technology, it is getting difficult to survive this situation without rapid development and introduction of high-valued products that satisfies needs in medical front.

Against this background, we will utilize the management resources of both companies of development, manufacturing and sales in an integrated and effective way cooperating with the Target Company that has a strong brand in the field of cardiovascular-related medical products. We are sure that the synergy of our business collaboration to make our position more powerful in Japan. Nipro Corporation considered that delisting of the Target Company is the best way for promoting the business deployment with agile management judgment to the Target Company and decided to conduct the Tender Offer.

### 2. Profile of the Target Company

(1) Company Name	Goodman Co., Ltd.
(2) Location	108, Fujigaoka, Meito-ku, Nagoya, Aichi
(3) Name and Title of Representative	Takehito Yogo, President
(4) Description of Business	Import, development, sale and manufacture of medical equipment and medical disposables
(5) Paid-in Capital	8,738,000,000 yen (as of September 30, 2012)
(6) Date of Incorporation	September 4, 1975

### 3. Outline of the Tender Offer

#### (1) Number of shares scheduled to be purchased

9,644,746 shares

In the Tender Offer, the maximum and minimum number of shares scheduled to be purchased is not set. Therefore, Nipro Corporation will make purchase all of the tendered shares.

The above number of shares scheduled to be purchased is maximum number of Target Company Shares that Nipro will make purchase in the tender offer. This number is obtained by adding (a) 6,874,426 shares obtained by subtracting the number of treasury shares held by the Target Company as of September 30, 2012 (160,500 shares) as set forth in the 38<sup>th</sup> second quarter report submitted by the Target Company on November 9, 2012 (the "Quarterly Report") and the common stocks of the Target Company held by ITOCHU Corporation that has agreement on not tendering to this offer (4,008,000 shares) from the total number of issued shares of the Target Company as of September 30, 2012 (11,042,926 shares) as set forth in the Quarterly Report, (b) 2,023,820 shares given put option (conversion option) for common stock value (94,000 shares ) that is obtained by subtracting the number of class A preferred stock redeemed by the Target Company (669,000 shares) from the total number of class A preferred stock issued by the Target Company as of January 24, 2013 (763,000 shares), would exercise on January 23, 2013, the preceding business day of the date when the Tender Offer was decided, to convert 1 share of class A preferred stock to 21.53 shares of common stocks, and (c) 746,500 shares of total

common shares underlying the stock acquisition right as of May 31, 2012 (7,465) as set forth in the 37<sup>th</sup> securities report submitted by the Target Company on June 29, 2012.

(2) Price of tender offer

- (a) 337 yen per common stock
- (b) 7,255 yen per class A preferred stock
- (c) 1 yen per 1 stock acquisition right

(3) Tender offer period

From January 25, 2013 (Friday) through March 8, 2013 (Friday) (30 business days)

(4) Purchase Price

3,250 million yen

(Note): Purchase price is an amount calculated by multiplying the number of shares to be purchased in the Tender Offer (9,644,746 shares) by the Tender Offer Price (337 yen).

(5) Commencement date of settlement

March 15, 2013 (Friday)